Methods for diagonosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory

Claim 1

A method for diagnosing the onset or monitoring the progression of dementia comprising; (i) measuring the total serum concentration of albumin and total CSF concentration of albumin for one or more healthy individuals and one or more individuals afflicted with a dementia; (ii) deriving default values of normal and altered albumin quotients from said measurements; (iii) deriving concentrations of normal and altered forms of serum albumin or normal and altered forms of CSF albumin for a patient using said default values of said albumin quotients and measured albumin concentrations of the patient to determine baseline values of said normal and altered albumin concentrations for said patient; and (iv) diagnosing the onset or monitoring the progression of dementia in a patient by tracking concentrations of said forms of albumin relative to said baseline values.

Claim 2

A method for diagnosing the onset or monitoring the progression of dementia comprising; (i) measuring the total serum concentration of albumin and total CSF concentration of albumin for one or more healthy individuals and one or more individuals afflicted with a dementia; (ii) deriving default values of normal and altered albumin quotients from said measurements; (iii) deriving concentrations of normal and altered forms of serum albumin or normal and altered forms of CSF albumin for a patient using said default values of said albumin quotients and measured albumin concentrations of the patient to determine baseline values of said normal and altered albumin concentrations for said patient; and (iv) diagnosing the onset or monitoring the progression of dementia in a patient by tracking concentrations of said forms of albumin relative to said baseline values.

Claim 5

A method for diagnosing the onset or monitoring the progression of dementia comprising; (i) measuring the total serum concentration of albumin and total CSF concentration of albumin for one or more healthy individuals and one or more individuals afflicted with a dementia; (ii) deriving default values of normal and altered albumin quotients from said measurements; (iii) deriving concentrations of normal and altered forms of serum albumin using said measured albumin concentrations and said default values of said albumin quotients; (iv) measuring total serum albumin-Al and total serum albumin-Mg binding constants for one or more individuals; (v) deriving default values for normal and altered albumin-Al and normal and altered albumin-Mg binding constants from said total binding constant measurements and said derived values for said normal and altered serum albumin concentrations; (vi) measuring total serum albumin-Al and total serum albumin-Mg binding constants for an individual patient; (vii) deriving an indicator of the concentration of altered albumin in one of serum or CSF of said patient using at least said measured total binding constants and said default values of said normal and altered binding constants; and (viii) diagnosing the onset or monitoring the progression of dementia by tracking values of said indicator over time.

Claim 6

A method for diagnosing the onset or monitoring the progression of dementia comprising; (i) measuring the total serum concentration of albumin and total CSF concentration of albumin for one or more healthy individuals and one or more individuals afflicted with a dementia; (ii) deriving default values of normal and altered albumin quotients from said measurements; (iii) deriving concentrations of normal and altered forms of serum albumin using said measured albumin concentrations and said default values of said albumin quotients; (iv) measuring total serum albumin-Al and total serum albumin-Mg binding constants for one or more individuals; (v) deriving default values for normal and altered albumin-Al and normal and altered albumin-Mg binding constants from said total binding constant measurements and said derived values for said normal and altered serum albumin concentrations; (vi) measuring total serum albumin-Al and total serum albumin-Mg binding constants for an individual patient; (vii) deriving an indicator of the concentration of altered albumin in one of serum or CSF of said patient using at least said measured total binding constants and said default values of said normal and altered binding constants; and (viii) diagnosing the onset or monitoring the progression of dementia by tracking values of said indicator over time.

Claim 9

A method for diagnosing the onset or monitoring the progression of dementia comprising; (i) measuring the total serum concentration of albumin and total CSF concentration of albumin for one or more healthy individuals and one or more individuals afflicted with a dementia; (ii) measuring total serum and CSF albumin-Al and total serum and CSF albumin-Mg binding constants for one or more individuals; (iii) deriving default values for normal and altered albumin-Al and normal and altered albumin-Mg binding constants from said binding constant measurements and said measured albumin concentrations; (iv) measuring total serum albumin-Al and total serum albumin-Mg binding constants for an individual patient; (v) deriving an indicator of the concentration of altered albumin of said patient using at least said measured binding constants and said default values of said normal and altered binding constants; and (vi) diagnosing the onset or monitoring the progression of dementia by tracking values of said indicator over time.

Claim 10

A method for diagnosing the onset or monitoring the progression of dementia comprising; (i) measuring the total serum concentration of albumin and total CSF concentration of albumin for one or more healthy individuals and one or more individuals afflicted with a dementia; (ii) measuring total serum and CSF albumin-Al and total serum and CSF albumin-Mg binding constants for one or more individuals; (iii) deriving default values for normal and altered albumin-Al and normal and altered albumin-Mg binding constants from said binding constant measurements and said measured albumin concentrations; (iv) measuring total serum albumin-Al and total serum albumin-Mg binding constants for an individual patient; (v) deriving an indicator of the concentration of altered albumin of said patient using at least said measured binding constants and said default values of said normal and altered binding constants; and (vi) diagnosing the onset or monitoring the progression of dementia by tracking values of said indicator over time.

Claim 13

A method for diagnosing the onset or monitoring the progression of dementia comprising; (i) determining, with respect to a patient, at least one of: (1) the ratio of the concentrations of normal and altered forms of serum albumin, (2) the ratio of the concentrations of normal and altered forms of CSF albumin, (3) the fractions of normal and altered forms of albumin in serum, and (4) the fractions of normal and altered forms of albumin in CSF; and (ii) tracking the change in said at least one ratio or fraction periodically, by determining the relative change in concentrations of said normal and altered forms of albumin over time.

Claim 14

A method for diagnosing the onset or monitoring the progression of dementia comprising; (i) determining, with respect to a patient, at least one of: (1) the ratio of the concentrations of normal and altered forms of serum albumin, (2) the ratio of the concentrations of normal and altered forms of CSF albumin, (3) the fractions of normal and altered forms of albumin in serum, and (4) the fractions of normal and altered forms of albumin in CSF; and (ii) tracking the change in said at least one ratio or fraction periodically, by determining the relative change in concentrations of said normal and altered forms of albumin over time.

Claim 17

A method for diagnosing the onset or progression of dementia comprising: (i) measuring at least one indicator of the concentration of a form of altered albumin in one of the serum or CSF of a patient; and (ii) diagnosing the onset or monitoring the progression of dementia by monitoring the value of said indicator over time.

Claim 18

A method for diagnosing the onset or progression of dementia comprising: (i) measuring at least one indicator of the concentration of a form of altered albumin in one of the serum or CSF of a patient; and (ii) diagnosing the onset or monitoring the progression of dementia by monitoring the value of said indicator over time.